Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice

Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid change, glucose homeost...

詳細記述

書誌詳細

主要な著者:	Geng-Ruei Chang, Po-Hsun Hou, Wei-Cheng Yang, Chao-Min Wang, Pei-Shan Fan, Huei-Jyuan Liao, To-Pang Chen
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-03-01
シリーズ:	Pharmaceuticals
主題:	doxepin obesity chromium fatty liver disease renal impairment glucose intolerance
オンライン･アクセス:	https://www.mdpi.com/1424-8247/14/3/267
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!